OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Abstract
Cost-effectiveness analysis (CEA) aims to evaluate the additional amount of health that an intervention provides to patients and how much more it costs compared to alternatives. While many health systems have used CEA for decades to inform coverage or reimbursement policies, in the US, it is now a contested political issue. One group of critics contend that CEA may be used to identify patient subgroups who are cost-ineffective to treat, resulting in treatment denials and discrimination. Recently, new perspectives on CEA argue that subgroups should be included to identify opportunities to advance health equity. Given these conflicting claims, this paper considers when subgroup analysis is justifiable and how results should be implemented.
This will be a hybrid seminar in the Richard Doll Building Lecture Theatre or on Zoom (medsci.zoom.us/j/92573286349).
